Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) and Zymeworks (NYSE:ZYME) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.


This table compares Epirus Biopharmaceuticals and Zymeworks’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Epirus Biopharmaceuticals N/A N/A N/A
Zymeworks -102.78% -24.44% -19.13%

Earnings and Valuation

This table compares Epirus Biopharmaceuticals and Zymeworks’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Epirus Biopharmaceuticals N/A N/A N/A N/A N/A
Zymeworks $53.02 million 19.98 -$36.56 million ($1.26) -21.41

Epirus Biopharmaceuticals has higher earnings, but lower revenue than Zymeworks.

Volatility and Risk

Epirus Biopharmaceuticals has a beta of 6.01, indicating that its stock price is 501% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.

Insider & Institutional Ownership

50.0% of Zymeworks shares are held by institutional investors. 13.1% of Epirus Biopharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Epirus Biopharmaceuticals and Zymeworks, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Epirus Biopharmaceuticals 0 0 0 0 N/A
Zymeworks 0 1 6 0 2.86

Zymeworks has a consensus price target of $36.00, indicating a potential upside of 33.43%. Given Zymeworks’ higher probable upside, analysts clearly believe Zymeworks is more favorable than Epirus Biopharmaceuticals.


Epirus Biopharmaceuticals beats Zymeworks on 5 of the 9 factors compared between the two stocks.

About Epirus Biopharmaceuticals

EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.

About Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive News & Ratings for Epirus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epirus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.